表紙
市場調査レポート

C型肝炎の標的療法

Competitor Analysis: Targeted Therapy of Hepatitis C

発行 La Merie Publishing 商品コード 214060
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
C型肝炎の標的療法 Competitor Analysis: Targeted Therapy of Hepatitis C
出版日: 2011年08月31日 ページ情報: 英文 91 Pages
概要

当レポートでは、C型肝炎のための抗ウイルス治療について分析し、新たな標的に向けた分子研究開発の現状と企業別パイプラインについてまとめ、概略以下の構成でお届けします。

C型肝炎の標的療法

  • HCV(C型肝炎ウイルス)プロテアーゼ阻害剤
  • HCV RNAポリメラーゼ阻害剤
  • サイクロフィリン阻害剤
  • HCV NS5Aプロテイン阻害剤
  • HCV NS4B-RNA結合阻害剤
  • HCV治療用・予防用ワクチン
  • HCV治療用抗体
  • HCVウイルス侵入阻害剤
  • HCV複製阻害剤
  • 新たな作用機序:ウイルスおよび宿主細胞
  • TLR作動薬
  • C型肝炎研究開発パイプラインを標的とする様々な企業
  • La Marieについて

C型肝炎標的療法の研究開発パイプラインを推進する企業

  • Abbott
  • Achillion Pharmaceuticals
  • Alios Biopharma
  • Altor Biosciences
  • Anadys Pharmaceuticals
  • Astexa Therapeutics
  • Avila Therapeutics
  • Bionor Immuno
  • Biotica Technology
  • Biotron
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • C-Pharma
  • Can-Fite BioPharma
  • Chimerix
  • ChronTech Pharma
  • Compass Biotechnologies
  • Conatus Pharmaceuticals
  • CureTech
  • Cytheris
  • Debiopharma
  • Dynavax Technologies
  • Eiger Pharmaceuticals
  • Enanta Pharmaceuticals
  • Epiphany Biosciences
  • Epixis
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • GlobeImmune
  • Heat Biologics
  • Idenix Pharmaceuticals
  • Idera Pharmaceuticals
  • Inhibitex
  • Inovio
  • Intellektualniy Dialog
  • Intercell
  • iTherX Pharmaceuticals
  • 日本たばこ
  • Johnson & Johnson
  • Medivir
  • Massachusetts Biologic Laboratories
  • Merck & Co.
  • 三菱田辺製薬
  • Morningside Asia Benture
  • Novartis
  • Okairos
  • 小野薬品工業
  • Padadin Biosciences
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmasset
  • Presidio Pharmaceuticals
  • Progenics Pharmaceuticals
  • Regulus Therapeutics
  • Replicor
  • Roche
  • Rosetta Genomix
  • Samaritan Pharmaceuticals
  • Santaris Pharma
  • SCYNEXIS
  • Tacere Therapeutics
  • TaiGen Biotechnology
  • Teva Pharmaceutical Industries
  • Theravance
  • Transgene
  • Tripep
  • Vertex Pharmaceuticals
  • Viriome
  • Virionics
  • ViroBay

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: LMCA0113

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-α administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient' s quality of life.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

  • HCV Protease Inhibitors
  • HCV RNA Polymerase Inhibitors
  • Cyclophilin Inhibitors
  • HCV NS5A Protein Inhibitors
  • HCV NS4B-RNA Binding Inhibitors
  • Therapeutic & Preventative HCV Vaccines
  • Therapeutic HCV Antibodies
  • HCV Viral Entry Inhibitors
  • HCV Replication Inhibitors
  • Novel Mechanism of Action HCV Virus & Host Cell Targets
  • TLR Agonists
  • Various
  • Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
  • About La Merie

Corporate Targeted Hepatitis C Therapeutic R&D Pipelines

  • Abbott
  • Achillion Pharmaceuticals
  • Alios Biopharma
  • Altor Biosciences
  • Anadys Pharmaceuticals
  • Astex Therapeutics
  • Avila Therapeutics
  • Bionor Immuno
  • Biotica Technology
  • Biotron
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • C-Pharma
  • Can-Fite BioPharma
  • Chimerix
  • ChronTech Pharma
  • Compass Biotechnologies
  • Conatus Pharmaceuticals
  • CureTech
  • Cytheris
  • Debiopharm
  • Dynavax Technologies
  • Eiger Pharmaceuticals
  • Enanta Pharmaceuticals
  • Epiphany Biosciences
  • Epixis
  • Genmab
  • GenPhar
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Heat Biologics
  • Idenix Pharmaceuticals
  • Idera Pharmaceuticals
  • Inhibitex
  • Inovio
  • Intellektualniy Dialog
  • Intercell
  • iTherX Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson (J&J)
  • Medivir
  • Massachusetts Biologic Laboratories (MBL)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Morningside Asia Venture
  • Novartis
  • Okairos
  • Ono Pharmaceutical
  • Paladin Biosciences
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmasset
  • PTC Therapeutics
  • Presidio Pharmaceuticals
  • Progenics Pharmaceuticals
  • Regulus Therapeutics
  • Replicor
  • Roche
  • Rosetta Genomics
  • Samaritan Pharmaceuticals
  • Santaris Pharma
  • SCYNEXIS
  • Tacere Therapeutics
  • TaiGen Biotechnology
  • Teva Pharmaceutical Industries
  • Theravance
  • Transgene
  • Tripep
  • Vertex Pharmaceuticals
  • Viriome
  • Virionics
  • ViroBay

Table of Contents

1. Targeted Therapy of Hepatitis C

  • HCV Protease Inhibitors
  • HCV RNA Polymerase Inhibitors
  • Cyclophilin Inhibitors
  • HCV NS5A Protein Inhibitors
  • HCV NS4B-RNA Binding Inhibitors
  • Therapeutic & Preventative HCV Vaccines
  • Therapeutic HCV Antibodies
  • HCV Viral Entry Inhibitors
  • HCV Replication Inhibitors
  • Novel Mechanism of Action HCV Virus & Host Cell Targets
  • TLR Agonists
  • Various

2. Corporate Targeted Therapy of Hepatitis C R&D

  • Pipelines
  • Abbott
  • Achillion Pharmaceuticals
  • Alios Biopharma
  • Altor Biosciences
  • Anadys Pharmaceuticals
  • Astex Therapeutics

Competitor Analysis

  • Avila Therapeutics
  • Bionor Immuno
  • Biotica Technology
  • Biotron
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • C-Pharma
  • Can-Fite BioPharma
  • Chimerix
  • ChronTech Pharma
  • Compass Biotechnologies
  • Conatus Pharmaceuticals
  • CureTech
  • Cytheris
  • Debiopharm
  • Dynavax Technologies
  • Eiger Pharmaceuticals
  • Enanta Pharmaceuticals
  • Epiphany Biosciences
  • Epixis
  • Genmab
  • GenPhar
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Heat Biologics
  • Idenix Pharmaceuticals
  • Idera Pharmaceuticals
  • Inhibitex
  • Inovio
  • Intellektualniy Dialog
  • Intercell
  • iTherX Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson (J&J)
  • Medivir
  • Massachusetts Biologic Laboratories (MBL)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Morningside Asia Venture
  • Novartis
  • Okairos
  • Ono Pharmaceutical
  • Paladin Biosciences
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmasset
  • PTC Therapeutics
  • Presidio Pharmaceuticals
  • Progenics Pharmaceuticals
  • Regulus Therapeutics
  • Replicor
  • Roche
  • Rosetta Genomics
  • Samaritan Pharmaceuticals
  • Santaris Pharma
  • SCYNEXIS
  • Tacere Therapeutics
  • TaiGen Biotechnology
  • Teva Pharmaceutical Industries
  • Theravance
  • Transgene
  • Tripep
  • Vertex Pharmaceuticals
  • Viriome
  • Virionics
  • ViroBay
Back to Top